Please check your internet connection and try again.
# Pantoprazole
## Overview
Pantoprazole is a proton pump inhibitor (PPI) that suppresses gastric acid secretion.
## Primary Indications
* Gastroesophageal reflux disease (GERD) - erosive esophagitis and symptom relief
* Healing of erosive esophagitis
* Zollinger-Ellison syndrome
* Part of *Helicobacter pylori* eradication regimens
## Adult Dosing
* **GERD/Erosive Esophagitis:** 40 mg orally or intravenously (IV) once daily for up to 8 weeks. Maintenance therapy may be continued at 20-40 mg once daily.
* **Zollinger-Ellison Syndrome:** Starting dose is typically 40 mg orally or IV twice daily. Doses may be increased as needed. Maximum recommended oral dose is 240 mg daily, and maximum IV dose is 90 mg daily.
* ***H. pylori* Eradication:** Typically given as 40 mg orally twice daily in combination with antibiotics (e.g., amoxicillin and clarithromycin or metronidazole and clarithromycin) for 7-14 days.
## Pediatric Dosing
* **GERD (erosive esophagitis):**
* **1-5 years:** 10-20 mg orally once daily.
* **6-11 years:** 20 mg orally once daily.
* **12-16 years:** 40 mg orally once daily.
* Dosing for Zollinger-Ellison syndrome or *H. pylori* eradication in pediatric patients is less established and should be guided by specialist recommendations.
## Dose Adjustments
* **Hepatic Impairment:** For severe hepatic impairment, the recommended dose is 20 mg orally once daily. IV dosing may also require reduction.
## Contraindications
* Hypersensitivity to pantoprazole, substituted benzimidazoles, or any component of the formulation.
## Adverse Effects
Common adverse effects include headache, diarrhea, nausea, abdominal pain, dizziness, and flatulence. Long-term use may be associated with increased risk of *Clostridium difficile*-associated diarrhea, bone fractures (hip, wrist, spine), hypomagnesemia, and vitamin B12 deficiency.
## Key Drug Interactions
* **Drugs Dependent on Gastric pH:** PPIs can decrease the absorption of drugs requiring an acidic environment, such as ketoconazole, itraconazole, and certain antiretrovirals (e.g., rilpivirine, atazanavir).
* **Methotrexate:** PPIs may increase serum levels of methotrexate.
* **CYP2C19 Substrates:** Pantoprazole is a moderate inhibitor of CYP2C19 and may increase concentrations of drugs metabolized by this enzyme (e.g., clopidogrel). However, clinical significance for clopidogrel is debated.
## Monitoring
* Monitor for signs and symptoms of hypomagnesemia (e.g., muscle cramps, seizures, arrhythmias).
* Monitor for effectiveness and signs of adverse effects.
* Consider monitoring vitamin B12 levels with long-term therapy.
* Bone mineral density may be considered in patients at risk for osteoporosis.
## Clinical Pearls
* Administer oral pantoprazole 30 minutes before a meal.
* Do not crush or chew delayed-release tablets.
* IV formulation requires reconstitution and dilution; follow manufacturer instructions carefully.
* IV pantoprazole is generally used for patients unable to take oral medications or in acute settings.
***
**Disclaimer:** This information is intended for healthcare professionals and is not exhaustive. Always consult the most current prescribing information, institutional protocols, and patient-specific factors before making any treatment decisions.
